An investigation of the clinical endpoint of improvement in irritability among 89 pediatric and adult patients with autism spectrum disorder treated with escitalopram found no difference by CYP2C19 metabolizer status, although a secondary analysis demonstrated slower rate of change in dose over time for CYP2C19 ultra-rapid metabolizers [40]. Here, CYP2C19 is linked to autism spectrum disorder.